CellaVision Introduces Analyzers into the Japanese Market

In March 2008, the company established a subsidiary in Japan--CellaVision Japan K.K. (Yokohama, Japan). Official approval has been given for the subsidiary to market the company's analyzers in Japan.

The Japanese authority, Pharmaceuticals and Medical Device Agency (PMDA) issued the product registration. The Japanese subsidiary was opened during a ceremony at the Swedish Embassy in Tokyo on the September 11, 2008. On October 9-11, 2008, CellaVision's products will be presented at Japan's largest convention for clinical laboratory products, the Japanese Society for Clinical Laboratory Automation (JSCLA). Around 7,000 participants in the field of clinical chemistry are expected to attend.

"The establishment of our Japanese subsidiary is advancing according to plan and it is satisfying to now be active on the Japanese market. We hope to be completely operative before the end of the year,” said CellaVision's CEO Yvonne Martensson. "It is important for us to meet potential clients on site in order to demonstrate how also Japanese laboratories can benefit from CellaVision's digital morphology technology. We see considerable potential in the Japanese market.”

There are approximately 9,000 hospitals and 900 commercial laboratories in Japan, which has large potential for medical technology products in general. CellaVision will focus primarily on the 1,000 larger hospital and commercial laboratories that will benefit the most from automating their processes.

CellaVision develops software and hardware for automatic image analysis of cells and cell changes for applications in health and medical care. The company develops and markets systems for automatic differentials of white and red blood cell morphology, software for education, and for quality assurance of differentials.

Related Links:
CellaVision
Japanese Society for Clinical Laboratory Automation